Science Valuation, Funding & Investors

Science is valued at $1.5B as of March 2026.

Last Science valuation

$1.5B

Series C · Mar 2026

Last Science funding round

$230M

Series C · Mar 2026

Cumulative funding Science raised

$407M

across 4 funding rounds

Key investors in Science

  • Khosla Ventures
  • Y Combinator
  • Lightspeed Venture Partners
  • Quiet Capital
  • HOF Capital
  • Artis Ventures

Science Overview

About Science

Science is a clinical-stage medical technology company developing brain-computer interfaces for vision restoration, cognitive enhancement, and motor control. San Francisco-headquartered, it offers Axon neural probes, SciFi headstages, and Synapse protocols alongside implantable devices like PRIMA photovoltaic arrays for retinal diseases. The platform integrates neural recording, optogenetics, and software for modular neuroengineering applications.


Founded

2021

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$1.5B (Mar 2026)

Science Valuation

Science is currently valued at $1.5B, based on its Series C in March 2026.

The $230M round was led by Khosla Ventures and Lightspeed Venture Partners, with participation from Y Combinator, Julian Mann, HOF Capital, Quiet Capital and TCIM.

Science's valuation has moved from $1.5B at its undisclosed-stage round in June 2024 to $1.5B in March 2026, across 2 priced rounds.

Science valuation by funding round

Science valuation by funding round
DateStageValuation
Mar 2026Series C$1.5B
Jun 2024Undisclosed stage$1.5B

Science Funding History

Science has raised a total of $407M across 4 funding rounds.

Science's first fundraising round was a $47M seed round in July 2021. The most recent completed round was a $230M Series C in March 2026.

Science funding rounds

Science funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Mar 2026Series CKhosla Ventures (lead); Lightspeed Venture Partners (lead); Y Combinator; Julian Mann; HOF Capital; Quiet Capital; TCIM$230M$1.5B-
Apr 2025Undisclosed stageKhosla Ventures (lead); 885 Capital; Unbound Ventures$104M-Science Corp., founded by Max Hodak (Neuralink co-founder), raised $104 million (of a planned $110 million) in a funding round led by Khosla Ventures around April 14-16, 2025. The Alameda, California-based biotech develops advanced brain and eye technology, including experimental retina implants for eye diseases and brain implant systems in early development, plus research equipment. Investors include Jai Mahtani, Khosla Ventures, Sudeep Ramnani, and Unbound Ventures, positioning Science as a Neuralink competitor in the growing brain technology sector. The company is actively hiring with the new capital. Science's devices remain experimental and not approved for human use, focusing on R&D rather than commercial traction metrics. The funding supports development in brain tech amid investor interest in AI-adjacent hardware like implants. The round aligns with Khosla Ventures' activity in April 2025, where it led 10 deals amid a slow VC market. Contextually, Khosla Ventures invests in deep tech and biotech, with this round exemplifying their focus on transformative neurotechnology.
Jun 2024Undisclosed stage-$26M$1.5BScience Corp., founded by Max Hodak (co-founder and former president of Neuralink), develops brain-computer interface technology aiming to be the first to bring a brain implant product to market. The company also launched Vessel, a new business line focused on organ preservation using miniaturized perfusion technology to enable transport on commercial flights or maintenance at home by patients. Science Corp. raised $230 million in a Series C funding round, bringing its total funding to $490 million. Investors included Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT (a nonprofit investment firm targeting government-applicable solutions). A source close to the startup indicated a post-money valuation of $1.5 billion for this round. The company employs 150 people and is pushing to get its brain implant to patients.
Jul 2021SeedSerafund; Artis Ventures$47M--

Who has invested in Science?

11 investors have backed Science across its funding rounds, including Khosla Ventures, Y Combinator, Lightspeed Venture Partners, Quiet Capital, HOF Capital and Artis Ventures.

Lead investors include Khosla Ventures and Lightspeed Venture Partners.


Science Investors

Investors in Science by funding rounds participated
InvestorHQRoundsRoleFirst check
Khosla VenturesUnited StatesSan Francisco, CA2LeadApr 2025
Y CombinatorUnited StatesSan Francisco, CA1ParticipantMar 2026
SerafundCanadaVancouver1ParticipantJul 2021
885 CapitalUAEDubai1ParticipantApr 2025
Julian MannUnited StatesSan Francisco, CA1ParticipantMar 2026
Artis VenturesUnited StatesSan Francisco, CA1ParticipantJul 2021
HOF CapitalUnited StatesNew York City, NY1ParticipantMar 2026
Lightspeed Venture PartnersUnited StatesSan Francisco, CA1LeadMar 2026
Quiet CapitalUnited StatesSan Francisco, CA1ParticipantMar 2026

This data is available for Pro users. Sign up to see all 11 Science investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Science Competitors

Science competitors include listed companies like BoneSupport and Alpha Tau Medical, and private ones like Cornerstone Robotics, ZD Medtech, CMR Surgical and Spirit AI.

Public and private companies comparable to Science
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Cornerstone RoboticsHong KongHong KongPrivate--$1B-
ZD MedtechChinaShanghaiPrivate--$900M-
CMR SurgicalUnited KingdomCambridgePrivate--$3B-
Spirit AIChinaHangzhouPrivate--$1.5B-
BoneSupportSwedenSwedenPublicly listed$120M$21M$1.5B9.7x
Alpha Tau MedicalIsraelIsraelPublicly listed-($45M)$1.4B2659.7x

Science Public Comps

Science is still privately-owned, but its public comps include Savaria, Beijing Balance Medical, El.En. Group, BoneSupport, Shanghai MicroPort, Haier Biomedical, Nolato, Alpha Tau Medical, Alphatec Holdings and Nakanishi.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Savaria$655M$113M2.5x2.3x14.3x11.2x
Beijing Balance Medical$92M$37M15.9x-40.0x-
El.En. Group$680M$96M1.9x2.1x13.3x11.1x
BoneSupport$120M$21M11.8x9.7x67.1x36.2x
Shanghai MicroPort$201M$108M6.1x5.6x11.4x10.6x
Haier Biomedical$347M$54M3.6x3.4x23.7x22.2x
Nolato$965M$161M1.4x1.4x8.7x8.3x
Alpha Tau Medical-($45M)-2659.7x(30.1x)(26.5x)

This data is available for Pro users. Sign up to see all Science competitors and their valuation data.

Start Free Trial

Common questions about Science

When was Science founded?Science was founded in 2021.
Where is Science headquartered?Science is headquartered in San Francisco, CA, United States.
Is Science publicly listed?No, Science is a private, VC-backed company.
What is Science's valuation?Science was last valued at $1.5B in its Series C in March 2026.
How much funding has Science raised?Science has raised $407M across 4 funding rounds.
What was Science's last funding round?Science's last funding round was a $230M Series C in March 2026, led by Khosla Ventures and Lightspeed Venture Partners.
Who are Science's investors?Science's investors include Khosla Ventures, Y Combinator, Serafund, 885 Capital, Julian Mann, Artis Ventures, HOF Capital, Lightspeed Venture Partners, Quiet Capital, Unbound Ventures and 1 other.
Which companies are comparable to Science?Companies comparable to Science include Cornerstone Robotics, ZD Medtech, CMR Surgical, Spirit AI, BoneSupport and Alpha Tau Medical.

See companies similar to Science

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial